Literature DB >> 18484387

Using the ICF in economic analyses of Assistive Technology systems: methodological implications of a user standpoint.

Ingrid Schraner1, Desleigh De Jonge, Natasha Layton, Jane Bringolf, Agata Molenda.   

Abstract

PURPOSE: This paper identifies key methodological issues for economic analyses of costs and effectiveness of Assistive Technology (AT) systems based on the International Classification of Functioning, Disability and Health (ICF). Following the biopsychosocial model of the ICF, the paper explores the consequences for cost-effectiveness analyses of AT systems when a user centred approach is taken. In so doing, the paper questions the fiction of neutrality in economic analyses and discusses the distinction between weak and strong objectivity.
METHOD: Costs are measured as all resources used when providing a particular level of environmental facilitators and reducing environmental barriers for an AT user, while effectiveness is measured in terms of the resulting increase in activities and participation of the AT user. The ICF's fourth qualifier for activities and participation, which denotes performance without assistance is used to identify the additional performance achieved due to the particular environmental factors in the current situation (first qualifier). A fifth qualifier for activities and participation is introduced to denote performance with optimal assistance, and the fourth qualifier is then again used to identify the increase in activities and participation due to the environmental factors in the situation with optimal assistance.
RESULTS: The effectiveness that an AT user achieves in his or her current situation can be compared with the effectiveness he or she could achieve when provided with what is considered an optimal AT system based on current technologies and user priorities. This comparison throws into sharp relief the role of AT systems as well as of universal design (UD) in reducing environmental barriers for AT users in a way that is cost-effective for society as a whole.
CONCLUSION: Cost-effectiveness analysis based on the ICF can provide powerful economic evidence for how best to allocate existing funding for AT systems. We can identify three particular scenarios in which clear recommendations can be made. In addition, cost-effectiveness analysis provides a means to identify how society can comply with its obligation towards all its members in the most cost-effective way, using a combination of AT and UD.

Mesh:

Year:  2008        PMID: 18484387     DOI: 10.1080/09638280701800293

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  4 in total

1.  Wearables for Pediatric Rehabilitation: How to Optimally Design and Use Products to Meet the Needs of Users.

Authors:  Michele A Lobo; Martha L Hall; Ben Greenspan; Peter Rohloff; Laura A Prosser; Beth A Smith
Journal:  Phys Ther       Date:  2019-06-01

2.  Standardised assessment of functioning in ADHD: consensus on the ICF Core Sets for ADHD.

Authors:  Sven Bölte; Soheil Mahdi; David Coghill; Susan Shur-Fen Gau; Mats Granlund; Martin Holtmann; Sunil Karande; Florence Levy; Luis A Rohde; Wolfgang Segerer; Petrus J de Vries; Melissa Selb
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-02-12       Impact factor: 4.785

3.  Living with spinal cord injury in Mongolia: A qualitative study on perceived environmental barriers.

Authors:  Delgerjargal Dorjbal; Birgit Prodinger; Claudia Zanini; Baljinnyam Avirmed; Gerold Stucki; Sara Rubinelli
Journal:  J Spinal Cord Med       Date:  2019-01-11       Impact factor: 1.985

4.  The Gestalt of functioning in autism spectrum disorder: Results of the international conference to develop final consensus International Classification of Functioning, Disability and Health core sets.

Authors:  Sven Bölte; Soheil Mahdi; Petrus J de Vries; Mats Granlund; John E Robison; Cory Shulman; Susan Swedo; Bruce Tonge; Virginia Wong; Lonnie Zwaigenbaum; Wolfgang Segerer; Melissa Selb
Journal:  Autism       Date:  2018-01-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.